Over the past few months, we have been working on a project to include full interactions with the hepatitis B drugs which has involved assessing and adding ~6700 new interactions. Prior to the completion of this project, many of the interactions with the HBV drugs had not been assessed and were blank.
As part of this project we have added tenofovir alafenamide (Vemlidy®) as a new HBV drug and split the peginterferon alfa entries into peginterferon alfa-2a and peginterferon alfa-2b in order to provide more precise information.
A new printable Overview of Interactions chart has been created for the HBV drugs and this is available in the Prescribing Resources of the website.
